Awareness is the greatest agent for CHANGE and IMPROVEMENT

An interactive session was organized on 26th January 2023 highlighting the features of Capecitabine and Filgrastim.

From the Department of Pharmacy Dr.Darakhshan under the Supervision of the Head of Department Dr.Sobia Akhtar, emphasized about the Etiology, Indications, Doses, and counseling of the drug.

She highlighted the features of Capecitabine is indicated for adjuvant treatment of people with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen and treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen.

Umair Rasheed discussed the need for biosimilar compounds by Searle Pharmaceutical

Word thanks shared by Dr.Lubna Saleem, Medical Oncologist